Our Vision In Action

Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.

Pipeline
Program	DiscoveryIND-EnablingCLINICAL	Rights
Rights Program MALT1 Relapsed / Resistant Non-Hodgkin's Lymphoma	IND-Enabling	Schrödinger
Program CDC7 Hematological Cancers and Solid Tumors	Discovery	Schrödinger
Program WEE1 Gynecological Cancers and other Solid Tumors	Discovery	Schrödinger
Rights Program HIF-2α Renal Cell Carcinoma	Discovery	Schrodinger and Bristol Myers Squibb
Program SOS1 / KRAS KRAS-Driven Cancers	Discovery	Schrodinger and Bristol Myers Squibb
Program Undisclosed Programs Oncology, Immunology and Neurology	Discovery	Schrodinger and Bristol Myers Squibb
Rights Program DNA Damage Response Oncology	Discovery	Schrodinger and ZAI Lab

Rights

Collaborative Programs

We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. We currently have collaborative drug discovery programs with more than 10 companies.

Some of the companies include Ajax Therapeutics, Bright Angel Therapeutics, Faxian Therapeutics, Morphic Holding, Nimbus Therapeutics, Ono Pharmaceutical, Sanofi, ShouTi , Sun Pharma Advanced Research Company (SPARC), Takeda, and TB Alliance. These programs are being advanced by our collaborators in diverse therapeutic areas, including oncology, antifungals, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, neurodegenerative disease, and tuberculosis.

These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.